

Resource Summary Report

Generated by [dkNET](#) on Aug 28, 2026

TRAMP-C2

RRID:CVCL_3615

Type: Cell Line

Proper Citation

RRID:CVCL_3615

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3615

Proper Citation: RRID:CVCL_3615

Description: Cell line TRAMP-C2 is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Male

Disease: Carcinoma of the mouse prostate gland

Defining Citation: [PMID:9269988](#)

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: TRAMP-C2

Synonyms: TRAMP C2

Cross References: BTO:BTO_0005114, CLO:CLO_0009402, AddexBio:C0019006/5004, ATCC:CRL-2731, Wikidata:Q54972949

ID: CVCL_3615

Record Creation Time: 20220427T221633+0000

Record Last Update: 20260816T000007+0000

Ratings and Alerts

No rating or validation information has been found for TRAMP-C2.

No alerts have been found for TRAMP-C2.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 21 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Gao L, et al. (2026) Targeting PKMYT1 enhances antitumor immune responses to PD-L1 blockade in castration-resistant prostate cancer. Journal for immunotherapy of cancer, 14(1).

Subramani E, et al. (2026) Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancers. iScience, 29(6), 116184.

Brevi A, et al. (2026) Intercepting YAP Activation in Prostate Cancer Blocks Neuroendocrine Progression. Cancer research, 86(12), 2860.

Bach CA, et al. (2025) A novel sialylation pathway mediated by extracellular vesicles in aggressive prostate cancer. PloS one, 20(9), e0329014.

Arias-Badia M, et al. (2025) Sequential JAK inhibition enhances antitumor immunity after combined anti-PD-1 and anti-CTLA4. JCI insight, 10(7).

Champiat S, et al. (2025) Nanrilkefusp alfa (SOT101), an IL-15 receptor ?? superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers. Cell reports. Medicine, 6(2), 101967.

Lang PA, et al. (2025) Optimized arenaviruses with tumor-tropic mutations promote safe anti-tumor efficacy via sustainable immune modulatory properties. Cell reports. Medicine, 6(10), 102411.

Yeon M, et al. (2025) Parkin Induces Ubiquitination and Large Extracellular Vesicle Release of HMGB1 to Activate Antitumor Immunity. Cancer research, 85(24), 5033.

Luo Y, et al. (2025) Single-cell clonal lineage tracing identifies the transcriptional program controlling the cell fate decisions by neoantigen-specific CD8 + T cells. bioRxiv : the preprint server for biology.

Van Espen B, et al. (2024) RNF185 Control of COL3A1 Expression Limits Prostate Cancer Migration and Metastatic Potential. Molecular cancer research : MCR, 22(1), 41.

Wu J, et al. (2024) A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2R? strengthens T cell-mediated anti-tumor therapies. Cell reports. Medicine, 5(10), 101747.

Wang H, et al. (2024) Potentiating Salvage Radiotherapy in Radiorecurrent Prostate Cancer Through Anti-CTLA4 Therapy: Implications from a Syngeneic Model. *Cancers*, 16(16).

Santassusagna S, et al. (2023) Master Transcription Factor Reprogramming Unleashes Selective Translation Promoting Castration Resistance and Immune Evasion in Lethal Prostate Cancer. *Cancer discovery*, 13(12), 2584.

Linares JF, et al. (2022) The lactate-NAD⁺ axis activates cancer-associated fibroblasts by downregulating p62. *Cell reports*, 39(6), 110792.

Feng Y, et al. (2021) Mechanical Loading-Driven Tumor Suppression Is Mediated by Lrp5-Dependent and Independent Mechanisms. *Cancers*, 13(2).

Bordini J, et al. (2020) Iron Induces Cell Death and Strengthens the Efficacy of Antiandrogen Therapy in Prostate Cancer Models. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 26(23), 6387.

Ganaie AA, et al. (2020) Anti-S100A4 Antibody Therapy Is Efficient in Treating Aggressive Prostate Cancer and Reversing Immunosuppression: Serum and Biopsy S100A4 as a Clinical Predictor. *Molecular cancer therapeutics*, 19(12), 2598.

Lu Y, et al. (2020) Complement Signals Determine Opposite Effects of B Cells in Chemotherapy-Induced Immunity. *Cell*, 180(6), 1081.

Poggio M, et al. (2019) Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory. *Cell*, 177(2), 414.

Pai CS, et al. (2019) Clonal Deletion of Tumor-Specific T Cells by Interferon- γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. *Immunity*, 50(2), 477.